title: [Dendritic cell-based therapeutic cancer vaccines].
abstract: In recent years immunotherapy has revolutionized the treatment of patients with advanced cancer. The increased knowledge in the tumor immune-biology has allowed developing rational treatments by manipulation of the immune system with significant clinical impact. This rapid development has significantly changed the prognosis of many tumors without treatment options up to date. Other strategies have explored the use of therapeutic vaccines based on dendritic cells (DC) by inducing antitumor immunity. DC are cells of hematopoietic origin, constitutively expressing molecules capable to present antigens, that are functionally the most potent inducers of the activation and proliferation of antigen specific T lymphocytes. The CD8+ T cells proliferate and acquire cytotoxic capacity after recognizing their specific antigen presented on the surface of DC, although only some types of DC can present antigens internalized from outside the cell to precursors of cytotoxic T lymphocytes (this function is called cross-presentation) requiring translocation mechanisms of complex antigens. The induction of an effective adaptive immune response is considered a good option given its specificity, and prolonged duration of response. The DC, thanks to its particular ability of antigen presentation and lymphocyte stimulation, are able to reverse the poor antitumor immune response experienced by patients with cancer. The DC can be obtained from various sources, using different protocols to generate differentiation and maturation, and are administered by various routes such as subcutaneous, intravenous or intranodal. The wide variety of protocols resulted in heterogeneous clinical responses.
authors.affiliation: Laboratorio de Terapia Génica y Celular, Instituto de Investigaciones Médicas Aplicadas-CONICET, Universidad Austral, Derqui-Pilar, Buenos Aires, Argentina.
authors.forename: Manglio
authors.initials: M
authors.lastname: Rizzo
authors.affiliation: Centro de Investigaciones y Transferencia del Noroeste de Buenos Aires (CIT NOBA), Buenos Aires, Argentina.
authors.forename: Laura
authors.initials: L
authors.lastname: Alaniz
authors.affiliation: 1Laboratorio de Terapia Génica y Celular, Instituto de Investigaciones Médicas Aplicadas-CONICET, Universidad Austral, Derqui-Pilar, Buenos Aires, Argentina. E-mail: gmazzoli@austral.edu.ar.
authors.forename: Guillermo D
authors.initials: GD
authors.lastname: Mazzolini
mesh_terms: D017951:Antigen Presentation / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination / Q000379:methods*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines
keywords: cancer; dendritic cells; therapeutic vaccines